CLINICAL TRIALS PROFILE FOR DEPACON

All Clinical Trials for Depacon

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000439 ↗	Drug Treatment for Alcoholics With Bipolar Disorder	Completed	University of Pittsburgh	Phase 2	2000-10-01	The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00000439 ↗	Drug Treatment for Alcoholics With Bipolar Disorder	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2000-10-01	The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00203242 ↗	An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.	Completed	Abbott	N/A	2003-07-01	The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first.
NCT00203242 ↗	An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.	Completed	Thomas Jefferson University	N/A	2003-07-01	The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first.

Clinical Trial Conditions for Depacon

Condition Name

Condition Name for Depacon
Intervention	Trials
Shock,Hemorrhagic	2
Photosensitive Epilepsy	1
Trauma	1
Alcoholism	1

Condition MeSH

Condition MeSH for Depacon
Intervention	Trials
Epilepsy	2
Shock, Hemorrhagic	2
Epilepsy, Reflex	1
Wounds and Injuries	1

Clinical Trial Locations for Depacon

Trials by Country

Trials by Country for Depacon
Location	Trials
United States	7
Australia	1
Brazil	1

Trials by US State

Trials by US State for Depacon
Location	Trials
Michigan	2
Pennsylvania	2
Massachusetts	1
Tennessee	1
Missouri	1

Clinical Trial Progress for Depacon

Clinical Trial Phase

Clinical Trial Phase for Depacon
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Depacon
Clinical Trial Phase	Trials
Completed	6
Terminated	1

Clinical Trial Sponsors for Depacon

Sponsor Name

Sponsor Name for Depacon
Sponsor	Trials
Dr. Hasan Alam	2
Abbott	2
Thomas Jefferson University	1

Sponsor Type

Sponsor Type for Depacon
Sponsor	Trials
Other	7
Industry	3
NIH	1